Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year
In 2026, China's innovative drug outbound business development (BD) transactions continue to heat up and show strong momentum. According to the NextPharma database, as of February 25, there have been 44 outbound licensing (license-out) transactions involving Chinese innovative drugs this year, with an upfront payment of approximately USD 3.123 billion and a total amount reaching USD 53.276 billion. (Securities Daily)
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments